

Baricade-Preserve T1D newly-diagnosed study

Principal Investigator: Dr. Tom Elliott **SubInvestigators:** Dr. Dale Clayton, Dr. David Lee
Study coordinator & primary contact Marla Inducil MD, Hector Com MD, Glaiza Erfe MD
P: 604-628-7253 x 7011, minducil@bcdiabetes.ca gerfe@bcdiabetes.ca hcom@bcdiabetes.ca
Study location: [BCDiabetes: 400 - 210 West Broadway, Vancouver V5Y 3W2](#)

Summary: Baricade-Preserve is a Phase 3, Double-Blind, Randomized, Placebo-Controlled study of Baricitinib—a JAK inhibitor, to preserve Beta cell function in newly-diagnosed Type 1 Diabetes aged ≥ 1 to < 36 years. The trial will run for approximately 60 weeks, comprising 13 on-site visits from screening to safety follow-up. Participants will receive either 4mg or 2mg baricitinib or matching placebo, to be taken orally (tablet/oral suspension) daily for 52 weeks.

Hypothesis: Type 1 diabetes (T1D) is characterized by autoimmune destruction of the insulin producing pancreatic β cells. To optimize preservation of β cell mass and function, it is essential to intervene early in the course of the disease by targeting the autoimmune mechanism and thus preventing further destruction of the remaining β cells. **Baricitinib** is a JAK inhibitor that has immunomodulatory and anti-inflammatory effects. Direct and indirect evidence showed that baricitinib can preserve β cell function by blocking the JAK pathway which is involved in T1D pathogenesis.

Eligible Participants include:

- Individuals aged ≥ 1 to < 36 years of age
- Newly-diagnosed T1D (within 100 days prior to starting study intervention)
- Have at least one diabetes-related autoantibody (GADA, IAA, IA2A, ZnT8A)
- Stimulated C-peptide ≥ 0.2 nmol/L or Random C-peptide > 0.3 nmol/L
- Body weight ≥ 8 kg; BMI < 35 ; Bone age X rays for < 18 yrs of age

Treatment course and duration: The study consists of 3 periods: 4-week screening period (V1-V2), 52-week treatment period (V3-V10) and a 4-week safety follow-up period (V801). Randomized participants will take either 4mg or 2mg baricitinib or matching placebo orally daily during the treatment period. V2 (stimulated C-peptide), V3, V6 and V8-V10 are fasting visits with 2-hr MMTT.

Odds of receiving placebo: one third (2:1 (4mg or 2mg baricitinib : 4mg or 2mg placebo))

	Screening		Double-Blind Treatment								Safety Follow-up
			Baricitinib								
			Placebo								
Visit Number	1	2	3	4	5	6	7	8	9	10	801
Weeks from Randomization	-4 to 0		0	2	6	12	16	28	40	52	56

↑
↑

Randomization 2:1
Primary Endpoint

Study documents:

Informed Consent

[Conflict of Interest statement](#)

Short URL = https://bit.ly/baricadeT1_2